Published on 13 Sep 2022 on American City Business Journals
Red blood cell medicines company Rubius Therapeutics Inc. is laying off 160 people — 75% of its staff — as it throws out its platform ...
Start tracking your investments with Statfolio
Innovators across Massachusetts' life sciences industry are busy developing drugs and devices to...
Meanwhile, Insulet promoted two other executives. Mark Field, a former Thermo Fisher Scientific I...
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In...
In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range o...
A Cambridge biotech is set to become at least the 10th Massachusetts biotech company to shut down...
Pablo Cagnoni, who was CEO of the soon-to-shutter Rubius Therapeutics Inc. until earlier this yea...
Rubius Therapeutics Inc. is in the final days of its existence. The Flagship Pioneering spinout...
Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic altern...